SCHEMBL19974712

SCHEMBL19974712

COc1ccc(CNC(=O)C(=O)C(C)N(C=O)c2ccccc2OC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 3/20 0.45
CAPN1 P07384 3/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 3/20 0.44
LMNA P02545 2/20 0.43
RAB9A P51151 2/20 0.43
MAPK1 P28482 1/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975219 0.92 LMNA (0.47) MAPTALDH1A1CAPN1LMNARAB9A
SCHEMBL19975281 0.91 ALDH1A1 (0.45) CARM1PRMT6MAPTALDH1A1HSD17B10
SCHEMBL19974858 0.89 ALDH1A1 (0.48) ALDH1A1LMNARAB9AGABRPGABRD
SCHEMBL19974685 0.88 POLB (0.51) ALDH1A1LMNARAB9A
SCHEMBL28315333 0.86 CAPN1 (0.39) CARM1PRMT6MAPTALDH1A1CAPN1
SCHEMBL21183552 0.86 HPGD (0.51) MAPTALDH1A1HSD17B10NPC1RAB9A
SCHEMBL19975394 0.85 TACR1 (0.39) MAPTALDH1A1CAPN1HSD17B10LMNA
SCHEMBL21183556 0.85 ADORA2A (0.43) ALDH1A1CAPN1HSD17B10LMNARAB9A
SCHEMBL21176346 0.84 ALDH1A1 (0.56) MAPTALDH1A1LMNAKDM4E
SCHEMBL21183519 0.84 CTSD (0.43) MAPTALDH1A1CAPN1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C CARM1 3680/4885PRMT6 483/4885MAPT 4561/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C CARM1 4235/4885PRMT6 608/4885MAPT 4673/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C CARM1 3680/4885PRMT6 483/4885MAPT 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.